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Abstract: Bombesin-related peptides are a family of peptides whose prototype was discovered in 
amphibian skin and which exhibit a wide range of biological activities. Since the initial isolation of 
bombesin from Bombina bombina skin, diverse forms of bombesin-related peptides have been found 
in the skins across Anura. In this study, a novel bombesin-related peptide of the ranatensin 
subfamily, named ranatensin-HL, was structurally-characterised from the skin secretion of the broad-
folded frog, Hylarana latouchii, through combination of molecular cloning and mass spectrometric 
methodologies. It is composed of 13 amino acid residues, pGlu-RAGNQWAIGHFM-NH2, and 
resembles an N-terminally extended form of Xenopus neuromedin B. Ranatensin-HL and its C-
terminal decapeptide (ranatensin-HL-10) were chemically synthesised and subjected to in vitro 
smooth muscle assays in which they were found to display moderate stimulatory effects on rat 
urinary bladder and uterus smooth muscles with EC50 values in the range of 1–10 nM. The prepro-
ranatensin-HL was highly homological to a bombesin-like peptide from Rana catesbeiana at both 
nucleotide and amino acid levels, which might provide a clue for the taxonomic classification of 
ranid frogs in the future. 
Keywords: amphibian; peptides; mass spectrometry; molecular cloning; bombesin; smooth muscle 
 
1. Introduction 
Amphibian skin has long been known as a delicate and multifunctional organ which has played 
a plethora of fundamental roles in their survival for millions of years. Such roles include respiration, 
camouflage, temperature control and chemical defence against encountered predators and pathogens [1]. 
The latter function is dependent on the secretions of highly specialised granular glands spread on the 
dorsal skin surface which contain a multitude of biologically-active peptides including antimicrobials, 
anticarcinogens, pheromones, neuropeptides and protease inhibitors [2,3]. One common class of 
peptides found in amphibian skin is the bombesin-related peptides, whose prototype is represented 
by bombesin, a tetradecapeptide originally isolated from the skin of Bombina bombina by Anastasi et al. as 
early as 1971 [4]. To date, a large number of bombesin-like peptides have been purified from the skin 
secretions of other anurans and these include ranatensin and phyllolitorin from Rana and 
Phyllomedusa species, respectively [1,5–7]. 
In 1979, the first mammalian homologue of amphibian bombesin was isolated from porcine 
stomach based on its capability of stimulating gastrin release from porcine antral tissue and was 
named gastrin-releasing peptide (GRP) in accordance with [8]. Neuromedin B (NMB) was the second 
mammalian counterpart of bombesin that was discovered, being isolated in 1983 from porcine spinal 
Molecules 2017, 22, 1110 2 of 12 
 
cord extracts based on its stimulation of rat uterus contractility [9]. Extensive studies on mammalian 
bombesin-like peptides have revealed that although multiple forms of GRP and NMB are distributed 
in many mammalian tissues, they are the unique homologues of bombesin-like peptides existing in 
mammals [10]. 
In accordance with phylogenetic analyses, bombesin-like peptides can be grouped into three 
branches—the GRP branch, the NMB branch and the bombesin-related peptides branch—which reflect 
the specific peptides originally characterised in amphibians consisting of bombesin, ranatensin and 
phyllolitorin subfamilies [11,12]. These subfamilies are differentiated by their pharmacological actions, 
receptor selectivity and amino acids near their carboxyl terminus: members of the bombesin 
subfamily have a C-terminus of -Gly-His-Leu-Met-NH2; the ranatensins are terminated with -Gly-His-Phe-
Met-NH2; and the phyllolitorin group possess Gly-Ser-Phe/Leu-Met-NH2 at their C-terminals [1,13,14]. 
GRP and NMB can be classified into the bombesin and ranatensin subfamilies, respectively, due to 
their C-terminal structural homologies, yet the mammalian counterpart of phyllolitorins remain to 
be discovered, if they exist at all [10,15,16]. 
Amphibian skin bombesin-like peptides and their mammalian homologues have been shown to 
elicit various biological effects including direct action on extravascular smooth muscles, regulation 
of exocrine and endocrine secretion, autocrine tumour-growth effects, thermoregulation and 
mediation of satiety [11,17–21]. Such profound pharmacological effectiveness not only enables frogs 
to defend themselves against attacking predators like snakes, birds or mammals, but also provides 
scientists with many clues for understanding some aspects of disease pathogenesis and may assist in 
the diagnosis and/or therapy of some diseases. 
Here, the identification, structural characterisation, molecular cloning of biosynthetic precursor 
cDNA and pharmacological investigation of a novel bombesin-related peptide, named ranatensin-
HL, from the skin secretion of the broad-folded frog, Hylarana latouchii, are described. This peptide is 
a tridecapeptide which is essentially identical to Xenopus neuromedin B extended at its N-terminus 
by pGlu-Arg-Ala-. Both ranatensin-HL and its C-terminal decapeptide (ranatensin-HL-10), were 
synthesised and subjected to preliminary pharmacological analysis using rat urinary bladder and 
uterus smooth muscle preparations, indicating that they would evoke similar myotropic effects like 
most other bombesin-like peptides. 
2. Results 
2.1. Identification and Structural Characterisation of Ranatensin-HL 
Screening of reverse phase HPLC fractions of H. latouchii skin secretion for pharmacological 
activity using rat urinary bladder and uterus smooth muscle preparations resulted in identification 
of a significant contractile activity in fraction # 94, coincident with a small but discrete absorbance 
peak as shown in Figure 1. Analysis of this fraction using matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometry showed that it contained a single major peptide with 
mass of 1499.02 Da. The primary structure of this peptide was analysed by MS/MS fragmentation 
sequencing and subsequently confirmed by molecular cloning of the precursor-encoding cDNA to 
eliminate the L/I ambiguity (Figure 2). Bioinformatic analysis of the primary structure of the peptide 
using the National Centre for Biotechnology Information (NCBI) database indicated sequence 
identity with amino acids 46–58 of a bombesin precursor from Rana catesbeiana (Figure 3a) and the 
complete C-terminal 10-mer sequence was identical to a putative neuromedin-B peptide identified in 
the brain of Xenopus laevis (Figure 3b) [22]. Thus, this skin peptide was essentially an N-terminally 
extended form of Xenopus brain neuromedin B. As the C-terminal was -Gly-His-Phe-Met-NH2 
coincident with ranatensin subfamily peptides, this bombesin-related peptide was considered as a 
member of ranatensin group and was named ranatensin-HL (HL = Hylarana latouchii) in accordance 
with a practical nomenclatural system proposed by Simmaco et al. [23]. 
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Figure 1. Region of reverse phase HPLC chromatogram of the skin secretion of Hylarana latouchii.  
The elution position/retention time of the pharmacologically-active peptide (ranatensin-HL), is indicated 
(arrow). 
 
Figure 2. MS/MS fragmentation sequencing spectra of the bioactive peptide (ranatensin-HL) identified in 
the HPLC fraction of Hylarana latouchii skin secretion. Panel shows predicted singly and doubly 
charged b-ions and y-ions arising from MS/MS fragmentation. Observed ions are underlined and in 
bold typeface. 
(a)
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(b)
Figure 3. National Centre for Biotechnology Information-Basic Local Alignment Search Tool Protein 
Database (NCBI-BLASTp) analysis of the mature peptide amino acid sequence of ranatensin-HL. (a) 
Ranatensin-HL and bombesin precursor (Rana catesbeiana) amino acids 46–58 showing 100% identity. 
(Accession number: ACO51610.1); (b) Ranatensin-HL and neuromedin-B precursor (Xenopus laevis) 
amino acids 43–54 showing 92% identity (Accession number: NP 001079342.1); however, the C-terminal 
10-amino acid of ranatensin-HL and the putative mature neuromedin-B peptide [22] showed 100% 
identity. The predicted mature peptide domain is boxed. 
2.2. Molecular Cloning of Ranatensin-HL Biosynthetic Precursor-Encoding cDNA 
Using the Rapid Amplification of cDNA Ends (RACE) PCR strategy described previously [24], 
the full-length cDNA encoding the biosynthetic precursor of ranatensin-HL was successfully and 
repeatedly cloned from the H. latouchii skin secretion-derived cDNA library. The open-reading frame 
(ORF) of the precursor protein was much longer than that of other amphibian ranatensin precursors, 
consisting of 125 amino acid residues. However, the domain architecture of this protein was similar 
to the precursors of other ranatensins, composed of a putative signal peptide, an N-terminal 
extension peptide followed by a putative propeptide convertase processing site (-NVL-), a single 
copy of mature peptide and a C-terminal extension peptide containing a further convertase 
processing site (-KK-) and a glycyl residue amide donor (Figure 4). Bioinformatic analysis of both the 
open-reading frame nucleotide and amino acid sequences of the ranatensin-HL precursor using 
National Centre for Biotechnology Information-Basic Local Alignment Search Tool Nucleotide Database 
(NCBI-BLASTn) and NCBI-BLASTp searches, revealed an extremely high degree of sequence identity 
with those of the bombesin precursor identified from Rana catesbeiana (Figure 5) (unpublished).  
The nucleotide sequence of the precursor-encoding cDNA of ranatensin-HL has been deposited in 
the European Molecular Biology Laboratory (EMBL) Nucleotide Sequence Database under the 
accession code LN626611.2. 
2.3. Smooth Muscle Pharmacology 
Both ranatensin-HL and ranatensin-HL-10 were successfully synthesised by solid-phase Fmoc 
methodology and were purified using reverse phase HPLC; the degree of purity and the structural 
authenticity were confirmed by MALDI-TOF mass spectrometry and MS/MS fragmentation analysis. 
The synthetic replicates were used to construct dose-response curves using rat urinary bladder and 
uterus smooth muscles. They were found to possess a moderate stimulation of contraction in rat 
urinary bladder smooth muscle and increased the frequency of spontaneous contraction of rat uterus 
smooth muscle in a dose-dependent manner (Figure 6). More specifically, ranatensin-HL and 
ranatensin-HL-10 exhibited similar contractive effects on rat urinary bladder smooth muscle with 
EC50 values of 19.2 and 63.8 nM, respectively; while on the other hand, ranatensin-HL was more 
potent on rat uterus smooth muscle with an EC50 (5.4 nM) nearly 15 times lower than that of 
ranatensin-HL-10 (70.9 nM). 
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Figure 4. Nucleotide and open-reading frame translated amino acid sequences of cloned cDNA 
encoding the biosynthetic precursor of ranatensin-HL. The putative signal peptide is double-underlined, 
the mature peptide sequence is single-underlined and the stop codon is indicated by an asterisk. The 
proteolytic cleavage sites for the mature peptide are boxed. 
 
(a) 
 
(b) 
Figure 5. NCBI-BLAST analysis of the open-reading frame nucleotide and amino acid sequences of 
the ranatensin-HL biosynthetic precursor. (a) Ranatensin-HL ORF nucleotides 1–378 and bombesin 
precursor mRNA (Rana catesbeiana) nucleotides 63–440 showing 97% identity. (Accession number: 
BT081479.1); (b) Ranatensin-HL ORF amino acid 1–125 and bombesin precursor (Rana catesbeiana) 
amino acid 1–125 showing 94% identity. (Accession number: ACO51610.1). 
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Figure 6. Comparison of myotropic effects of synthetic ranatensin-HL and ranatensin-HL-10 on 
isolated rat urinary bladder and uterus smooth muscles. (a) Dose-response curves of ranatensin-HL 
and ranatensin-HL-10 using rat urinary bladder smooth muscle preparations. EC50 values were 
determined as 19.2 and 63.8 nM, respectively; (b) Dose-response curves of ranatensin-HL and ranatensin-
HL-10 using rat uterus smooth muscle preparations. EC50 values were determined as 5.4 and 70.9 nM, 
respectively. Each data point represents the mean and standard error of five determinations. 
3. Discussion 
Amphibian skin is a remarkable source of bioactive peptides and it was predicted by Vittorio 
Erspamer (1909–1999) that each skin peptide would have a counterpart in mammalian tissues [25]. 
The majority of these amphibian skin peptides share highly conserved biologically active cores with 
their endogenous mammalian counterparts [25–27]. Additionally, in some cases, the peptides from 
the skin may have a wider distribution in other tissues of the amphibian. Bombesin-related peptides 
are a class of peptides appearing in the skin of many species of amphibians but also expressed in their 
central nervous systems (CNS) as well as their gastrointestinal (GI) tracts [12]. At the same time, they are 
found to have their homologues—GRP and NMB—in mammalian CNS and GI tract at considerably 
lower levels than those expressed in amphibian skin [15,17]. 
All bombesin-related peptides from amphibian skin are characterised by a conserved C-terminal 
region with the structure of -WAXGXXM-NH2, but differ widely in their N-terminal regions [28,29]. 
In the current study, a bombesin-related peptide of the ranatensin subfamily has been identified from 
the skin secretion of Hylarana latouchii and it terminates in the canonical C-terminal amidated 
tetrapeptide sequence—Gly-His-Phe-Met-NH2. It was named ranatensin-HL. As shown in Figure 4, the 
ranatensin-HL precursor contained a processing site (-KK-) that resembled those (-KK-, -KR-, -RK-) at the 
C-terminals of bombesin-related peptides from other amphibians, in which a dibasic amino acid 
cleavage site is present at the C-terminus. The glutamine and glycine residues, respectively, provided 
the N-terminal pyroglutamyl residue and the amide for the C-terminal methionine. The precursor 
sequence alignment of ranatensin-HL with homologues from other ranid frogs is illustrated in  
Figure 7 [13,28–30], which shows that the overall structure of the ranatensin-HL precursor is distinct 
from those of other ranid frog precursors. Compared with the average size (about 80 residues) of 
bombesin-related peptide precursors identified from members of the Ranidae family, ranatensin-HL 
was processed from a much larger precursor of 125 amino acid residues containing a 67-mer  
C-terminal extension peptide. Moreover, it was notable that unlike the majority of bombesin-related 
peptide precursors previously cloned from ranid frog skins whose N-terminals were usually flanked 
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by the dibasic amino acid cleavage sites, Arg-Arg, Lys-Lys, Lys-Arg, Glu-Ala, Ala-Ala or Gly-Ala 
(Figure 7), ranatensin-HL was shown to be cleaved from its precursor following an Asn-Val-Leu 
sequence according to the structural analysis resulting from MS/MS fragmentation sequencing and 
this may represent a recognition sequence of a chymotryptic-like enzyme. Thus, the C-terminus of 
ranatensin-HL was released from the precursor by cleavage at dibasic amino acids; yet the  
N-terminus was released by a chymotryptic-like cleavage. In fact, the sizes and N-terminal processing 
patterns of bombesin-related peptide precursors differ significantly among different amphibian 
families but share similar properties within the same family, a factor which may be of possible use as 
a marker of taxonomic and molecular phylogenetics as suggested by Li et al. [30]. 
 
Figure 7. Sequence comparison of the precursors of bombesin-related peptides from different species 
of the Ranidae family. HL, Hylarana latouchii (this study); RP, Rana pipiens; RS, Rana shuchinae; SV, 
Sanguirana varians; OG1-OG3, Odorrana grahami. The sequences of mature peptide are underlined. The 
processing sites of the precursor for releasing mature peptides are boxed. The second possible 
processing sites are circled in some sequences. Gaps are introduced to optimise the sequence homology. 
Through the bioinformatic analysis of the primary structure of ranatensin-HL performed using 
the NCBI-BLASTp search, it revealed that the C-terminal 10-amino acids of ranatensin-HL were 
identical to the predicted end-product from a gene in the brain of Xenopus laevis, whose product was 
named Xenopus neuromedin B [22] (Figure 3b). In this study, this C-terminal decapeptide was named 
temporarily as ranatensin-HL-10 due to its homology with ranatensin-HL. What was intriguing was 
whether there was a difference in terms of bioactivity between these two forms of peptides and, 
hence, we chemically synthesised both and evaluated their corresponding myotropic effects by 
conducting smooth muscle pharmacological assays. In keeping with other bombesin-related peptides, 
both ranatensin-HL and ranatensin-HL-10 displayed prompt and moderate contractile effects on rat 
urinary bladder and uterus smooth muscles, suggesting that they act on the same receptor. 
As rantensin-HL and ranatensin-HL-10 possessed similar myoactivity, it prompted the thought 
that this alternative processing of ranatensin-HL to ranatensin-HL-10 might occur endogenously and 
that ranatensin-HL-10 might be present in the skin of H. latouchii and possibly that both may occur 
also in the frog’s brain. These questions would be interesting to address in future research. In the 
current study, ranatensin-HL-10 was not detected in the skin secretion of H. latouchii through either 
molecular cloning or bioactivity assessing of HPLC fractions; nevertheless, it could not exclude the 
probability of omission due to the trace amount present in the skin secretion and the detection 
limitation. Moreover, in the pharmacological bioassay, ranatensin-HL and ranatensin-HL-10 showed 
a similar potency on rat urinary bladder smooth muscle but differed in potency on rat uterus smooth 
muscle, indicating that the N-terminal region may contribute to myotropic potency to some extent. 
This result may likewise provide some clues for the future study of structure–function relationships 
of both peptides. Since bombesin receptors have a wide and specific distribution in mammals and 
display different affinities for different bombesin-related peptides, it would be meaningful to 
investigate the myoactivity of ranatensin-HL and ranatensin-HL-10 on other mammalian tissues, 
which may provide an opportunity for the discovery of a novel bombesin receptor and perhaps 
identify a ligand for the BBS-3 receptor. 
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An interesting finding in current study was the high degree of structural identity at both the 
nucleotide and amino acid levels, between the precursors of ranatensin-HL and a bombesin-like 
peptide found in Rana catesbeiana (Figure 5). As a matter of fact, Hylarana latouchii is a member of the 
genus Hylarana within the Ranidae family and is endemic to central and southern China, while  
Rana catesbeiana belongs to the genus Rana (now Lithobates) of the Ranidae family and is native to 
North America. Taking the high degrees of structural similarities of precursor sequences into 
consideration, even though these two species have significant zoogeographical isolation, it seems that 
either one of these genes has evolved from the other or both have evolved from a common ancestor. 
This could come about if both share a close evolutionary strategy which may result from adaption to 
a similar ecological niche. Since molecular aspects have been employed more frequently recently for 
taxonomic purposes, the current data would provide an additional insight into the taxonomic 
classification of ranid frogs and perhaps a more systematic approach to generic assignations within 
the Ranidae family [31,32]. 
4. Materials and Methods 
4.1. Specimen Biodata and Secretion Harvesting 
Specimens of Hylarana latouchii were captured in Fujian Province, P.R. China. All frogs were 
adults and skin secretion was harvested by mild electrical stimulation on the dorsal skin surface of 
the frogs according to the methods described previously [33]. The obvious white mucous secretion 
was washed off using deionised water, collected, snap-frozen in liquid nitrogen, lyophilised and 
stored at −20 °C prior to use. 
4.2. Reverse-Phase HPLC Fractionation of Skin Secretion 
Five milligrams of lyophilised H. latouchii skin secretion was dissolved in 1 mL of trifluoroacetic 
acid (TFA)/water (0.05/99.95, v/v) and clarified by centrifugation. The clear supernatant was decanted 
and subjected to reverse-phase HPLC fractionation using a Cecil Adept CE4200 HPLC system 
(Amersham Biosciences, Buckinghamshire, UK) fitted with a Jupiter C-5 semi preparative column 
(300 Å, 5 µm, 25 cm × 1 cm, Phenomenex, Macclesfield, Cheshire, UK) and a Powerstream HPLC 
software, being eluted with a linear gradient formed from 0.05/99.95 (v/v) TFA/water to 
0.05/19.95/80.00 (v/v/v) TFA/water/acetonitrile over 240 min at a flow rate of 1 mL/min. Fractions (1 mL) 
were collected automatically at 1 min intervals and the effluent absorbance was monitored at λ214 
nm. Samples (100 µL) were removed from each chromatographic fraction, lyophilised and stored at 
−20 °C prior to analysis of myoactivity using rat urinary bladder and uterus smooth muscle bioassays. 
4.3. Bioactivity Screening Using Rat Urinary Bladder and Uterus Smooth Muscles 
Female Wister rats (250–300 g) were euthanized by carbon dioxide asphyxiation followed by 
cervical dislocation in accordance with institutional animal experimentation ethics and UK animal 
research guidelines. Procedures had been vetted by the Institutional Animal Care and Use Committee 
(IACUC) of Queen’s University Belfast. The rats were laid on their dorsal surface, followed by 
incising along the mid ventral line to open the abdomen and dissecting the subcutaneous fat. The 
exposed urinary bladder and intact uterine horns were removed from each rat and placed in ice-cold 
Kreb’s solution (118 mM NaCl, 4.7 mM KCl, 25 mM NaHCO3, 1.15 mM NaH2PO4, 2.5 mM CaCl2,  
1.1 mM MgCl2 and 5.6 mM glucose) which was vigorously aerated with 95% O2 and 5% CO2.  
For urinary bladder smooth muscle preparations, muscle strips (2 mm × 10 mm) were dissected from 
the bladder under a dissection microscope and were pierced at each end by triangular hooks (0.2 mm 
diameter) which were tied with fine silk ligatures; for uterus smooth muscle preparations, each 
uterine horn was halved and 2 triangular hooks threaded the lumen. Then, the tissues were mounted 
on a transducer prior to placing in 2 mL organ baths containing Kreb’s solution at 37 °C following at 
2 mL/min with constant bubbling of 95% O2 and 5% CO2. The tissue preparations were equilibrated 
for 1 h before experimental procedures were initiated. Samples of sequential reverse phase HPLC 
fractions were reconstituted in 22 µL of Kreb’s solution and used to screen for smooth muscle activity. 
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4.4. Identification and Structural Characterisation of Peptide Possessing Bioactivity 
The reverse-phase HPLC fraction which was found to possess contractile activity on rat urinary 
bladder and rat uterus smooth muscles was initially analysed using MALDI-TOF MS (Voyager DE, 
PerSeptive Biosystems, Foster City, CA, USA) to determine the molecular mass. The major peptide 
present in the HPLC fraction was subjected to primary structural analysis by MS/MS fragmentation 
sequencing using an LCQ-Fleet electrospray ion-trap mass spectrometer (Thermo Fisher Scientific, 
San Francisco, CA, USA). 
4.5. Molecular Cloning of the Peptide Biosynthetic Precursor-Encoding cDNA 
A 5 mg sample of lyophilised skin secretion was dissolved in 1 mL of cell lysis/mRNA protection 
buffer supplied by Dynal Biotec, Wirral, UK. Polyadenylated mRNA was isolated using magnetic 
oligo-dT beads as described by the manufacturer (Dynal Biotech, Merseyside, UK), and was 
subsequently reverse-transcribed. The resultant cDNA library was subjected to 5’ and 3’-RACE 
procedures to obtain full-length prepro-peptide nucleic acid sequence data using a SMART-RACE 
kit (Clontech, Palo Alto, CA, USA) essentially as described by the manufacturer. Briefly, the 3’-RACE 
reactions employed a Nested Universal Primer (NUP) primer (supplied with the kit) and a 
degenerate sense primer (S: 5’-ARMGIGCIGGIAAYCARTGGGC-3’) that was complementary to the 
N-terminal amino acid sequence, pGlu-RAGNQWA-, of the bioactive peptide. PCR products were 
gel-purified and cloned using a pGEM-T vector system (Promega Corporation, Southampton, UK) 
and sequenced using an ABI 3100 automated sequencer (Applied Biosystems, Foster City, CA, USA). 
The sequence data obtained from the 3’-RACE product was used to design a specific antisense primer 
(AS: 5’-CGTATCTCAGGCACAAATATATA-3’) to a defined conserved site within the 3’ non-
translated region of the peptide encoding transcript. 5’-RACE reaction was carried out using this 
primer in conjunction with the NUP primer and generated PCR products were gel-purified, cloned 
and sequenced as described above. 
4.6. Solid-Phase Peptide Synthesis of Ranatensin-HL and Ranatensin-HL-10 
Once the unequivocal primary structure of the bombesin-like peptide (ranatensin-HL) had been 
established through MS/MS fragmentation sequencing and translating cloned cDNA, it was 
synthesised by solid-phase Fmoc chemistry using a PS3 automated solid-phase peptide synthesiser 
(Protein Technologies, Tucson, AZ, USA). Products were purified by reverse-phase HPLC, and the 
degree of purity and authenticity of structure were confirmed by MALDI-TOF MS and MS/MS 
fragmentation sequencing. In addition, the C-terminal decapeptide of ranatensin-HL (ranatensin-HL-10) 
was also synthesised and purified in the same way. 
4.7. Pharmacological Assay of Synthetic Peptides Using the Rat Urinary Bladder and Uterus  
Smooth Muscles 
Solutions of synthetic peptides, ranging in concentration from 10−2 to 104 nM, were made in 
Kreb’s solution and were used to construct dose-response curves. They were added to the bladder 
and uterus muscle strips which were put under 0.5 g of tension, in increasing concentrations with 10 
min washes and 10 min equilibration periods between each dose. Each concentration of peptides was 
applied to a minimum of five muscle strips. Changes in tension of the bladder muscle strips were 
recorded and amplified through pressure transducers connected to a PowerLab System (AD 
Instruments Pty Ltd., Oxford, UK), while changes in spontaneous contraction frequency of the uterus 
smooth muscle preparations were recorded instead. Data were analysed to obtain the mean and 
standard error of responses by Student’s t-test and dose-response curves were constructed using a 
“best-fit” algorithm through the data analysis package provided. Responses were plotted as changes 
in grams of tension (for urinary bladder) or changes in spontaneous contraction frequency  
(for uterus) against final molar concentration of peptides present in the organ baths. 
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5. Conclusions 
In this study, a bombesin-related tridecapeptide, ranatensin-HL (pGlu-RAGNQWAIGHFM-NH2), 
from the skin secretion of Hylarana latouchii, was structurally and pharmacologically-characterised. 
The precursor of ranatensin-HL was found to be highly identical to that of a bombesin-like peptide 
from Rana catesbeiana at both nucleotide and amino acid levels. The complete C-terminal 10-amino 
acids of mature ranatensin-HL (ranatensin-HL-10) was the same as Xenopus brain neuromedin B, thus 
ranatensin-HL was considered as the N-terminally extended form of neuromedin B. In the smooth 
muscle pharmacological assay, both ranatensin-HL and ranatensin-HL-10 exhibited moderate 
stimulation of contraction in rat urinary bladder and uterus smooth muscles. 
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